Compare uniQure N.V. Ordinary Shares (QURE) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs Taskus Inc — how do they compare? uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B), while Taskus Inc trades at $8.1 (market cap $750.00M). The key difference: uniQure N.V. Ordinary Shares is the larger of the two by market cap, and Taskus Inc is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Taskus Inc for 35 Days on average.
| QURE | TASK | |
|---|---|---|
Market Cap | $1.48B | $750.00M |
Volume | 2,488,780 | 195,383 |
Sector | Health | Technology |
52-Week High | $70.59 | $14.30 |
52-Week Low | $9.03 | $4.57 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $728.62M | $1.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TaskUs (TASK) trades at $8.14, up 1.88% with bullish technical signals from moving averages. The company shows strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expanding to 8.75%. Valuation metrics appear attractive with P/E of 7.05 and P/S of 0.62. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.28 expected, driven by AI services growth offsetting declines in other segments.
The outlook remains positive with analyst consensus price target of $9.33 representing 15% upside potential. Key opportunities include AI services expansion growing 26% annually, while risks involve margin compression from higher labor costs and client concentration. Institutional ownership increased with Dimensional Fund Advisors raising stake by 12.8% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
